Journal Mobile Options
Table of Contents
Vol. 126, No. 3, 2011
Issue release date: September 2011
Acta Haematol 2011;126:152–156
(DOI:10.1159/000328997)

Acute Promyelocytic Leukemia with a Smoldering Course Associated with Therapy-Related Myelodysplastic Syndrome

Wolach O. · Yeshurun M. · Amariglio N. · Shpilberg O. · Raanani P.
aInstitute of Hematology, Davidoff Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, bSackler School of Medicine, Tel Aviv University, Tel Aviv, and cSheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Acute promyelocytic leukemia (APL) may appear rarely as a late complication of the treatment of other primary cancers. Therapy-related APL (tAPL) differs from de novo APL in epidemiological and clinical parameters but shares common molecular signatures and does not differ in survival end- points. We describe a 67-year-old female patient who presented with an atypical course of tAPL. Atypical features in this patient’s course included a preceding therapy-related myelodysplastic syndrome (MDS) with a slowly expanding pathological promyelocyte clone. Following treatment with all-trans-retinoic acid and arsenic trioxide, the patient achieved complete clinical, morphological and molecular remission. Review of the pertinent literature highlights the rarity of MDS transforming into APL, although dysplasia has been shown to be a possible feature of tAPL. MDS may be an underdiagnosed stage in tAPL leukomogenesis. This case also underscores the complexity of clinical decision-making in the context of tAPL.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Buchner T, Dohner H, Burnett AK, Lo-Coco F: Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemianet. Blood 2009;113:1875–1891.
  2. Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J: Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:395–400.
  3. Pulsoni A, Pagano L, Lo Coco F, Avvisati G, Mele L, Di Bona E, Invernizzi R, Leoni F, Marmont F, Mele A, Melillo L, Nosari AM, Pogliani EM, Vignetti M, Visani G, Zagonel V, Leone G, Mandelli F: Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the Gimema experience. Blood 2002;100:1972–1976.
  4. Beaumont M, Sanz M, Carli PM, Maloisel F, Thomas X, Detourmignies L, Guerci A, Gratecos N, Rayon C, San Miguel J, Odriozola J, Cahn JY, Huguet F, Vekhof A, Stamatoulas A, Dombret H, Capote F, Esteve J, Stoppa AM, Fenaux P: Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21:2123–2137.
  5. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C: Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002;99:1909–1912.
  6. Ogawa K, Shineha H, Abe R, Shichishima T, Kimura H, Yui T, Kawaguchi M, Matsuda S, Uchida T, Kariyone S: Acute promyelocytic leukemia with a history of RAEB in transformation and the 15/17 translocation (in Japanese). Rinsho Ketsueki 1989;30:67–71.
  7. Haferlach T, Schoch C, Loffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Gruneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wormann B, Heinecke A, Sauerland MC, Buchner T, Hiddemann W: Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003;21:256–265.

    External Resources

  8. Yin CC, Glassman AB, Lin P, Valbuena JR, Jones D, Luthra R, Medeiros LJ: Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia. Am J Clin Pathol 2005;123:840–848.
  9. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H: Use of all-trans-retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006;107:3469–3473.
  10. Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, Parry A, Walz C, Wiemels JL, Segal MR, Ades L, Blair IA, Osheroff N, Peniket AJ, Lafage-Pochitaloff M, Cross NC, Chomienne C, Solomon E, Fenaux P, Grimwade D: DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005;352:1529–1538.
  11. Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF: Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 2006;24:2456–2464.
  12. Vey N, Bosly A, Guerci A, Feremans W, Dombret H, Dreyfus F, Bowen D, Burnett A, Dennis M, Ribrag V, Casadevall N, Legros L, Fenaux P: Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 2006;24:2465–2471.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50